NCT00719394已完成1 期
Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-136 Administered Orally to Healthy Japanese Male Subjects and Healthy Japanese Elderly Male Subjects
Wyeth is now a wholly owned subsidiary of Pfizer1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2008年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Safety and tolerability of GSI-136 as evaluated from reported adverse events, scheduled physical examinations, vital sign measurements, orthostatic vital sign measurements, cardiac rhythm monitoring, 12-lead ECGs, and clinical laboratory test results.
研究概览
简要总结
This is a first-in-human study of GSI-136, a gamma-secretase inhibitor being developed for the treatment of Alzheimer disease. This study will take place in Japan only and will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GSI-136 after administration of ascending single oral doses to healthy Japanese male subjects and healthy Japanese elderly male subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
GSI 136
Experimental
干预措施: GSI 136 (Drug)
placebo
Placebo Comparator
干预措施: placebo (Drug)
结局指标
主要结局
Safety and tolerability of GSI-136 as evaluated from reported adverse events, scheduled physical examinations, vital sign measurements, orthostatic vital sign measurements, cardiac rhythm monitoring, 12-lead ECGs, and clinical laboratory test results.
时间窗: 6 months
次要结局
- Pharmacokinetics as evaluated from the blood and urine concentrations of GSI-136; Pharmacodynamics as evaluated from the levels of select biomarkers in the blood and the administration of a visual analog scale to measure sedation effects.(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study GSI-136 in Healthy Young and Healthy Elderly SubjectsAlzheimer DiseaseHealthyNCT00718731Wyeth is now a wholly owned subsidiary of Pfizer80
已完成
1 期
Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese MalesArrhythmiaNCT00543946Wyeth is now a wholly owned subsidiary of Pfizer56
已完成
1 期
Single Ascending Dose Study of SRA-444 in Healthy SubjectsAlzheimer DiseaseNCT00452504Wyeth is now a wholly owned subsidiary of Pfizer64
已完成
1 期
Study Evaluating Single Ascending Doses Of ILS-920Acute Ischemic StrokeNCT00827190Wyeth is now a wholly owned subsidiary of Pfizer16
已完成
1 期
First Time in Human Study Using GSK2330672Diabetes Mellitus, Type 2NCT01416324GlaxoSmithKline17